Background {#Sec1}
==========

Rheumatoid arthritis (RA) is a common chronic autoimmune disease predominantly affecting synovial joint, and is characterized with joint swell, erosion, pain and mobility limitation \[[@CR1]\]. RA usually causes early unemployment, physical disability, reduced life expectancy and mortality, imposing substantial global social burden \[[@CR2]--[@CR4]\]. In addition to joint manifestations, RA patients also frequently accompanied with extra-articular involvements, which significantly increase the morbidity and mortality of RA patients. Studies reported that about half of RA patients will develop respiratory disorders during their life time \[[@CR5], [@CR6]\]. Among which, pulmonary diseases were demonstrated as the second leading cause of death of RA patients, account for nearly 20% of the morbidity \[[@CR7]\]. Besides the well-known RA-associated interstitial lung disease (ILD) and bronchiectasis, airway diseases were also illustrated to associate with RA recently, such as chronic obstructive pulmonary disease (COPD) \[[@CR8], [@CR9]\].

COPD is a chronic progressive inflammatory disease of the distal airways and associated with the chronic inflammation of airways and lung. COPD is characterized with the persistent airflow limitation resulting from inhaling noxious particles and gases \[[@CR10], [@CR11]\]. In addition to these risk factors as cigarette smoke, recent studies also reported that the autoimmune response was also contributing to COPD \[[@CR12]--[@CR14]\]. Recently, literatures have reported the pathologic role of autoimmunity in the development of COPD, but the authentic relationship between COPD and autoimmunity diseases, such as RA, was still unclear. Nannini and colleagues first reported that the incidence of COPD in RA patients was significant higher than patients without RA at 2013 \[[@CR15]\]. A recent meta-analysis also reminded the tendency of comorbidity of COPD in RA patients, with the limitation of synthesizing the evidence of only four original studies before December 2014 \[[@CR16]\]. Since then, new studies have continually reported the relationship between RA and COPD \[[@CR17], [@CR18]\]. Besides, meta-analysis focus on the prevalence of COPD in RA patients was still devoid. Therefore, we conducted the present meta-analysis to evaluate the risk and prevalence of COPD in RA patients comprehensively.

Methods {#Sec2}
=======

This meta-analysis was conducted under the guidance of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) standard \[[@CR19]\] (Additional file [1](#MOESM1){ref-type="media"}: Table S1) and the Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines for systematic reviews of observational studies \[[@CR20]\] (Additional file [1](#MOESM1){ref-type="media"}: Table S2).

Review questions {#Sec3}
----------------

In accordance with the PICOs scheme, the primary review question of present meta-analysis was the RR of COPD (outcome) in RA patients (patient) compared with controls without RA (comparison) of cohort study (study design); the second review question was the prevalence of COPD (outcome) in RA patients (patient) of observational study (study design).

Search strategies and selection criteria {#Sec4}
----------------------------------------

Two reviewers (Yubo Ma, Hui Tong) independently searched Cochrane Library, PubMed and Web of Science from inception to April 30, 2018 and main search strategy was detailed in the Additional file [1](#MOESM1){ref-type="media"}: Figure S1. Besides, pertinent literatures were also manually searched through the references of relevant original studies and reviews. When necessary, the corresponding authors were contacted for full text and detailed data. Eligible studies must respectively fulfill the following included criteria for different outcomes. Primary outcome: a) cohort studies reported the incidence risk of COPD in RA patients compared with controls; b) studies present hazard ratio (HR), risk ratio(RR), standardized incidence ratio (SIR) or original data eligible for the calculate of these indexes. And for the secondary outcome: a) observational studies reported the data of prevalence of COPD in RA; b) selection of RA patients without explicit selection bias. For studies reported duplicate population, the most comprehensive studies contained more participants were included. Additional, all the included studies must written by English.

Methodological quality assessment and data extraction {#Sec5}
-----------------------------------------------------

Newcastle-Ottawa Scale (NOS) for cohort study and 11-item checklist recommended by Agency for Healthcare Research and Quality (AHRQ) for observational study were applied for the methodological quality assessment of included studies by two investigators (Yubo Ma, Hui Tong) independently. Data about RR and prevalence of COPD were also independently extracted by two reviewers to calculate effect sizes. For the further exploration of the relationship between COPD and RA, the following characteristics were also extracted from included studies: publication year, first author's name, region of study, study design, the time of study conduct, diagnosis criterion of RA and COPD, disease duration of RA patients and the number, age, gender distribution, follow up duration and smoker proportion of participants. Any discrepancy in processes of literature research, study selection, quality assessment and data extraction was resolved by discussion of the reviewers for consensus.

Statistical analysis {#Sec6}
--------------------

The pooled RR and prevalence with 95% confidence interval (CI) were calculated to assess the risk and prevalence of COPD in RA patient, through either random effects model or fixed effect model depended on the between studies heterogeneity. Cochran's Q statistic was used to assess the between studies heterogeneity, and *I*^2^ test was also used complemented to quantify the degree of inconsistency by calculating the percentage of total between studies variation due to heterogeneity rather than chance. Significant between studies heterogeneity was define as the *P* \<  0.05 of Q test or *I*^2^ \> 50% \[[@CR21]\]. The fixed effect model was used where there was no significant heterogeneity, otherwise random effects model was used \[[@CR22], [@CR23]\]. Funnel plot, Egger's linear regression and Begg's rank correlation test were performed to evaluate publication bias qualitatively and quantitatively \[[@CR24], [@CR25]\]. Subgroup analysis for categorical variable and meta-regression for continuous variable were used for exploring potential source of heterogeneity. Sensitivity analysis was also performed to assess the viability of meta-analysis via omitting individual study consecutively. Any *P* \<  0.05 was considered statistically significant, and all the statistical analyses were conducted by STATA 11.0 (StataCorp, College Station, TX).

Results {#Sec7}
=======

Literature research and study characteristics {#Sec8}
---------------------------------------------

A total of 1466 relevant studies were searched from PubMed (*n* = 419), Web of Science (*n* = 1046) and Cochrane library (n = 1). After the removal of 336 replicate studies and title and abstract screening, 84 studies were retrieved for the full test review. Two studies were removed for reporting data of duplicate population before qualitative synthesis and 14 studies met the inclusion criteria eventually, of which six studies \[[@CR15], [@CR17], [@CR18], [@CR26]--[@CR28]\] reported the risk of COPD and eight studies \[[@CR2], [@CR29]--[@CR35]\] presented the data of the prevalence of COPD in RA (see Fig. [1](#Fig1){ref-type="fig"}). All the studies were published between 2010 and 2017, and the methodological quality of included studies were all satisfied, with NOS score among 6 to 9 and AHRQ 11-item checklist scores among 5 to 9. Explicit characteristics of the included studies were represented in Table [1](#Tab1){ref-type="table"}, Table [2](#Tab2){ref-type="table"} and Table S3 in Additional file [1](#MOESM1){ref-type="media"}.Fig. 1Flow chart of the literature search and study selectionTable 1Characteristics of included studies reported the risk of COPD in RAAuthorYearRegionNumber of casesNumber of controlsAge of cases(Y)Age of controls(Y)Female proportion (%)Follow up duration(Y)QualitySparks JA \[[@CR17]\]2017America843839959.859.8100.07.09Mcguire K \[[@CR18]\]2017Canada246252539657.257.367.018.69Hemminki K \[[@CR26]\]2011SwedenNANANANANANA6Nannini C \[[@CR15]\]2013America59459657.858.273.416.39Ursum J \[[@CR27]\]2013Netherlands3356670855.055.063.72.88Shen TC \[[@CR28]\]2014China2872511490053.853.278.05.19*NA* Not available, *Y* yearTable 2Characteristics of included studies reported the prevalence of COPD in RAAuthorYearRegionNumber of patientsAge (Y)Female proportion (%)Smoker proportion (%)Disease duration (Y)QualityBieber V \[[@CR29]\]2013Israel903960.177.928.9NA7Carmona L \[[@CR30]\]2011Spain332059.079.214.910.36Liao TL \[[@CR31]\]2016China4218053.478.6NANA6Aurrecoechea E \[[@CR32]\]2016Spain14051.450.028.681.95Lacaille D \[[@CR33]\]2017Canada1411657.566.6NA0.49Curtis JR \[[@CR34]\]2015America1329652.681.9NANA5Lunt M \[[@CR35]\]2010England1619457.973.422.39.97Dougados M \[[@CR2]\]2013Multination392056.081.713.29.69*NA* Not available, *Y* Year

RR of COPD in RA {#Sec9}
----------------

Six literatures reported the RR of COPD in RA patients, ranged from 1.52 to 2.57, contained more than 58143 RA patients and 15999 controls. The pooled RR of subsequent incident COPD in RA was 1.82 (95% CI = 1.55 to 2.10, *P* \<  0.001) with significant between study heterogeneity (*I*^2^ = 75.4%; Tau^2^ = 0.08, *P* = 0.001) (see Fig. [2](#Fig2){ref-type="fig"}). Meta-regression on factors as sample size, age and female proportion of cases, follow up duration and methodological quality indicated that none of them was the source of heterogeneity, but publication year (coefficient = − 0.0772, t = − 4.31, *P* = 0.013, Table [3](#Tab3){ref-type="table"}). Subgroup analysis also reported that RRs of different subgroups were stable according to region of research and diagnosis criteria of RA and COPD detailed in Table [4](#Tab4){ref-type="table"}. By omitting each study consequently, sensitivity analysis found that study by Hemminki and colleagues could explain 66.3% of heterogeneity. After omission, the pooled RR was turned to 1.72 (95% CI = 1.58 to 1.87, *P* \<  0.001; *I*^2^ = 18.0%; Tau^2^ = 4.88, *P* = 0.300). Funnel plot of RR was symmetric visually (Additional file [1](#MOESM1){ref-type="media"}: Figure S2), with Egger's linear regression (t = − 0.46, *P* = 0.606) and Begg's rank correlation (*Z* = 0.38, *P* = 0.707) showing no significant publication bias (Additional file [1](#MOESM1){ref-type="media"}: Figure S3).Fig. 2Forest plots of the RR and prevalence of COPD in RA: A) Forest plot of the RR of COPD in RA; B) Forest plot of the prevalence of COPD in RATable 3Meta-regression analysis coefficients of risk ratio and prevalence of COPDVariablesCoefficient (SE)95% CIt*P*Risk ratio Publication year−0.0772 (0.0179)\[− 0.1270,-0.0275\]−4.310.013 Age of cases−0.0387(0.0185)\[− 0.0975, 0.0201\]−2.100.127 N of cases\<  0.0001(\<  0.0001)\[\< −0.0001, 0.0002\]0.870.450 N of controls\<  0.0001(\<  0.0001)\[\< −0.0001, \<  0.0001\]1.830.164 N of participants\<  0.0001(\<  0.0001)\[\< −0.0001, \<  0.0001\]1.780.174 Female proportion0.0025(0.0019)\[−0.0037, 0.0086\]1.280.290 Follow up duration−0.0112 (0.0066)\[−0.0320, 0.0097\]−1.700.187 Quality−0.2916 (0.1396)\[−0.6793, 0.0962\]−2.090.105 Beginning of cohort−0.0085 (0.0053)\[−0.0232, 0.0062\]−1.610.182 Duration of cohort0.0073 (0.058)\[−.0088, 0.0233\]1.250.278Prevalence Publication year0.0045 (0.0040)\[−0.0052, 0.0143\]1.140.296 Number of cases\<  0.0001(\<  0.0001)\[\< −0.0001, \<  0.0001\]1.420.206 Age of cases−0.0011 (0.0036)\[−0.0099, 0.0078\]− 0.300.777 Female proportion−0.0015 (0.0011)\[−0.0042, 0.0012\]−1.360.221 Smoker proportion0.0031 (0.0006)\[0.0012, 0.0049\]5.330.013 Disease duration0.0005 (0.0004)\[−0.0008, 0.0019\]1.320.239 Quality−0.0015 (0.0071)\[−0.0188, 0.0159\]− 0.210.844CI: confidence interval; N: number; SE: standard errorTable 4Subgroup analysis of risk ratio and prevalence of COPDSubgroups*N*Effect size\[95% CI\]*ZP*Test of heterogeneity*I* ^2^*P*Risk ratio Region  North America31.560 \[1.320, 1.769\]14.58\<  0.0010.0%0.968  Europe22.194 \[1.439, 2.948\]5.70\<  0.00184.7%0.011  Asia11.850 \[1.695, 2.005\]23.39\<  0.001NANA  Overall61.822 \[1.546, 2.099\]12.92\<  0.00175.4%0.001 RA diagnosis  Database code31.560 \[1.320, 1.769\]14.58\<  0.0010.0%0.968  Universal criteria32.062 \[1.608, 2.517\]8.89\<  0.00182.9%0.003  Overall61.822 \[1.546, 2.099\]12.92\<  0.00175.4%0.001 COPD diagnosis  Database code51.881 \[1.569, 2.192\]11.82\<  0.001NANA  Self-reported11.520 \[1.120, 1.920\]7.45\<  0.00177.7%0.001  Overall61.822 \[1.546, 2.099\]12.92\<  0.00175.4%0.001Prevalence Region  Asia20.092 \[0.081, 0.104\]15.78\<  0.00192.1%\<  0.001  Europe30.052 \[0.033, 0.070\]5.58\<  0.00193.1%\<  0.001  North America20.048 \[0.013, 0.084\]2.650.00899.5\<  0.001  Multination10.040 \[0.034, 0.046\]12.79\<  0.001NANA  Overall80.062 \[0.041, 0.083\]5.74\<  0.00199.5%\<  0.001 RA diagnosis  Database code50.067 \[0.040, 0.094\]4.86\<  0.00199.7%\<  0.001  ACR criteria30.041 \[0.031, 0.051\]7.900.03969.3%\<  0.001  Overall80.062 \[0.041, 0.083\]5.74\<  0.00199.5%\<  0.001 COPD diagnosis  Database code60.062 \[0.038, 0.086\]4.99\<  0.00199.6%\<  0.00  NA20.065 \[0.007, 0.123\]2.190.02881.8%0.002  Overall80.062 \[0.041, 0.083\]5.74\<  0.00199.5%\<  0.001*CI* Confidence interval, *N* Number of study

Prevalence of COPD in RA {#Sec10}
------------------------

Eight studies containing 102205 RA patients reported the primary prevalence of COPD between 3.0 and 10.0%. Meta-analysis demonstrated that the pooled prevalence of COPD was 6.2% (95% CI = 4.1 to 8.3%) with significant heterogeneity (*I*^2^ = 99.5%; Tau^2^ \<  0.01, *P* \<  0.001). Likewise, meta-regression illustrated that all the factors of publication year, quality of study and sample size, age, female proportion and disease duration were not the cause of heterogeneity, except smoker proportion (see Table [3](#Tab3){ref-type="table"}). The prevalence of COPD was positively associated with smoker proportion of RA patients (coefficient = 0.0031, t = 5.33, *P* = 0.013). Subgroup analysis demonstrated that the prevalence of different subgroups were consistent. Meanwhile, sensitivity analysis indicated that the pooled effect size was stable whenever any study was omitted. The funnel plot was visually symmetry (Additional file [1](#MOESM1){ref-type="media"}: Figure S2) with Begg's rank correlation (*Z* = 0.37, *P* = 0.711) and Egger's linear regression (t = − 0.17, *P* = 0.873) (Additional file [1](#MOESM1){ref-type="media"}: Figure S4) presenting the absence of publication bias.

Discussion {#Sec11}
==========

Joint destruction and diffused inflammation of RA usually cause reduced quality of life, disability and mortality of patients \[[@CR2]\]. Besides, RA related extra-articular manifestations and comorbidities also caused the exacerbated outcome of RA patients. RA-associated ILD was the most well-known pulmonary manifestation with the prevalence around 5--10% \[[@CR36]--[@CR38]\]. Studies reported that ILD and cardiovascular disease are the primary causes of premature death of RA patients, and the 1-year, 5-yaer and 10-year mortality of RA-associated ILD were 13.9, 39.0 and 60.1% \[[@CR8], [@CR39], [@CR40]\]. In addition to the pulmonary manifestation, recent studies also reported the increased risk of COPD in RA \[[@CR17], [@CR18], [@CR41]\]. Hyldgaard and colleagues also reported the astonished excess burden of COPD in RA patients that the 1-year and 5-year mortalities of RA patients with COPD were 15.0 and 41.9%. Meanwhile, they demonstrated that COPD associated mortality was no less than ILD in RA patients using data derived from identical medical registries and the same methodology \[[@CR8], [@CR41]\]. The present analysis reported a statistically significant increased risk of incident COPD with the excess risk of 85%. Potential reasons accounting for the increased risk were present as following.

First, studies proposed that RA and COPD have the similar autoimmune pathogenesis \[[@CR10], [@CR12], [@CR42], [@CR43]\]. COPD Patients were also demonstrated to detect autoantibodies to a broad spectrum of self-antigens in serum \[[@CR43]--[@CR45]\]. Patients with genetic and environmental factors susceptible to RA were reported prone to abnormal immune response in pulmonary interstitium and airway \[[@CR46]\].

In the other side, studies also reported that smoking may work as a confounding associated with both RA and COPD and result in no-causal association between RA and COPD. It is known that smoking was the main independent risk factor of COPD \[[@CR47]\], and tobacco use could increase the predisposition of RA through peptidylarginine deiminases, protein citrullination and the processes of oxidative stress and epigenetic changes. So the more smokers in RA cohort may lead to more COPD in RA patients. Nevertheless, Sparks and colleagues also reported that the RRs of COPD in RA patients were 1.43 adjusted smoking in the entire population and 1.31 in the subset of nonsmokers. Study also reported that smoking cessation of RA patients with COPD would not attenuate the pulmonary inflammation \[[@CR17], [@CR46]\].

Third, RA patients usually accompanied with systemic inflammation affecting multiple organs. Long-term chronic inflammation was reported to damage the endothelial cell and cause diverse diseases including atherosclerosis \[[@CR48]\]. Likewise, diffuse chronic inflammation in lung of RA may cause lasting destruction of normal construction of pulmonary alveoli and increase the susceptibility to COPD. Therefore, we have reasons to hypothesize that COPD and RA share similar pathogenesis of self reactive immune response, and human comorbidity with RA would increase the risk of concurrent COPD, even smoking may actor as a confounding.

Meanwhile, we have also concluded that the pooled prevalence of COPD among RA patients was 6.2% and positively correlated with the proportion of smokers. In our included studies, three studies reported that the incidence of COPD of RA patients were 2.07, 2.79 and 5.25 per 1000 person-years respectively \[[@CR18], [@CR26], [@CR28]\]. Besides, study by Shen also reported that the incidences of subgroups aged 20--34, 35--49, 50--64 and over 65 years were 0.48, 1.09, 4.09 and 17.2 per 1000 person-years \[[@CR28]\]. Taken into account of the astonished 1-yaer and 5-year mortality of RA associated COPD, rheumatologist should pay enough attention to the regular monitoring of COPD, especially of aged patients or patients with COPD risk factors like smoking. RA patients should also withdraw tobacco smoking as early as possible not only for the control of disease activity of RA but for the prevention of COPD.

There are still some limitations should be taken into consideration. First, due to the limited information of original studies, only few factors were evaluated to explore the influence on effect size in meta-regression and subgroup analysis, and characteristics, such as smoker proportion of RA cohorts and controls, may work as confounder between RA and COPD and result in inconclusive causal association. Second, still a proportion of the included studies reported the incidence risk and prevalence of COPD based on the data of single medical center but not regional medical data, which would lead to some certain selection bias of patients and inconsistence of results. Third, the present meta-analysis only can provide observational and correlative evidence because of study design and observational nature of original studies. Lastly, significant heterogeneity of the meta-analysis may restrict the generalizability of the results.

Conclusions {#Sec12}
===========

The present meta-analysis has demonstrated the significant increased risk and high prevalence of COPD in RA patients. Rheumatologist should pay attention to the monitoring of COPD in RA patients, and patients had better quit tobacco use as early as possible. Further research is still required for the exploration of cellular and molecular mechanism underlying the association between COPD and RA.
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Additional file 1:**Table S1.** PRISMA checklist. **Table S2.** MOOSE checklist. **Table S3.** Detailed characteristics of included studies. **Figure S1.** Search strategy of the electrical databases. **Figure S2.** Funnel plots on the RR and prevalence of COPD in RA: A) Funnel plot on the RR of COPD in RA; B) Funnel plot on the prevalence of COPD in RA. **Figure S3.** Funnel plots of Egger's linear regression and Begg's rank correlation test of RR of COPD in RA: A) Begg's rank correlation; B) Egger's linear regression. **Figure S4.** Funnel plots of Egger's linear regression and Begg's rank correlation test of prevalence of COPD in RA patients: A) Begg's rank correlation; B) Egger's linear regression. (DOCX 580 kb)
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